Neurizon Therapeutics

Neurizon Secures Global Trademark Protection Across Key Markets

Neurizon has secured registered trademark protection for NEURIZON across all priority global markets, including the United States, the European Union, the United Kingdom, Australia and Japan Completion of the US registration represents an important milestone supporting the Company’s long-term commercialisation strategy in its primary value-creation market All registrations cover Class 42 services, including pharmaceutical research...

FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial

FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the HEALEY ALS Platform Trial Next steps include obtaining single IRB approval, site initiations and clinical start-up activities ahead of commencement of patient enrollment expected early...

HEALEY ALS Platform Trial Preparation Shows Positive Respiratory Outcome of NUZ-001

Updates to HEALEY ALS Platform Trial Master Protocol have been made to enhance the potential of establishing a clinically meaningful outcome for patients, including: Treatment period extended from 24 to 36 weeks to allow longer evaluation of treatment effects Inclusion Criteria modified for time since symptom onset from 36 to 24 months to enrich the...
Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Australia

+61 (3) 9692 7222